Program
andexanet alfa
Also written as “Andexanet”, “Andexanet alfa” and “Andexanet alfa (infusion IV)”.
Its studies are mostly in Hemorrhage · Thrombosis, led by AstraZeneca.
Furthest: phase 4, since Aug 30, 201814 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 140 open or running | phase 4since Aug 30, 2018 | Dec 18, 2012 | none ahead |
Also a collaborator on its studies: parexel and portola-pharmaceuticals-llc-a-wholly-owned-subsidiary-of-ale.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 18, 2012First study: phase 2 study in Healthy VolunteersFirst studyNCT01758432 · 54 enrolled · United States
- Dec 27, 2012Phase 1 study in HealthyNCT03218241 · 32 enrolled · United States
- Apr 28, 2014Phase 3 study in HemorrhageNCT02207725 · 68 enrolled · United States
- Aug 18, 2014Phase 3 study in HemorrhageNCT02220725 · 80 enrolled · United States
- Dec 18, 2014Phase 3 study in HemorrhageNCT02329327 · 479 enrolled · United States, Belgium, Canada and more
- Mar 7, 2017Phase 1 study in HemorrhageNCT03083704 · 153 enrolled · United States
- Sep 27, 2017Phase 2 study in HemorrhageNCT03330457 · 18 enrolled · United States
- May 15, 20183 phase 2 studies in Healthy VolunteersNCT03578146, NCT03551743, NCT03551730
- Aug 30, 2018Phase 4 study in ThrombosisNCT03661528 · 530 enrolled · United States, Austria, Belgium and more
- Jan 14, 2020Phase 2 study in ThrombosisNCT04233073 · 10 enrolled · United States, Austria, France and more
- Jun 9, 2023Phase 3 study in Urgent SurgeryNCT05926349
- Nov 27, 2025Phase 1 study in Healthy ParticipantsNCT07312851 · 191 enrolled · Germany, United Kingdom
TargetBeta
TFPI →read by rule
“Rivaroxaban sequestering agent; Apixaban sequestering agent; Tissue factor pathway inhibitor inhibitor”ChEMBL 37, by rule
Other programs on TFPI
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| marstacimabrule | Pfizer | phase 3 | 10 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07312851Healthy Participants · Germany, United Kingdom | 1 | Completed | Jun 22, 2026 | 191 |
| NCT05926349Urgent Surgery | 3 | Withdrawn | Jan 5, 2027 | 0 |
| NCT04233073Thrombosis · United States, Austria, France and more | 2 | Terminated | Nov 23, 2021 | 10 |
| NCT03661528Thrombosis · United States, Austria, Belgium and more | 4 | Completed | May 27, 2023 | 530 |
| NCT03578146Healthy Volunteers | 2 | Completed | Sep 2015 | 48 |
| NCT03551743Healthy Volunteers | 2 | Completed | Sep 2015 | 28 |
| NCT03551730Healthy Volunteers · United States | 2 | Completed | Sep 2015 | 27 |
| NCT03330457Hemorrhage · United States | 2 | Terminated | Feb 22, 2016 | 18 |
| NCT03083704Hemorrhage · United States | 1 | Completed | Sep 28, 2017 | 153 |
| NCT02329327Hemorrhage · United States, Belgium, Canada and more | 3 | Completed | Sep 24, 2020 | 479 |
| NCT02220725Hemorrhage · United States | 3 | Completed | Aug 2015 | 80 |
| NCT02207725Hemorrhage · United States | 3 | Completed | Apr 2015 | 68 |
| NCT03218241Healthy · United States | 1 | Completed | Sep 2012 | 32 |
| NCT01758432Healthy Volunteers · United States | 2 | Completed | Sep 2015 | 54 |
How it is read
Names in the registry
- “Andexanet”, 3 entries
- “Andexanet alfa”, 2 entries
- “andexanet alfa”, 2 entries
- “Andexanet alfa (infusion IV)”, 1 entry
- “Andexanet alfa (Gen 1 Process 2)”, 1 entry
Conditions, from the studies’ own filings
- Hemorrhage, 5 studies
- Thrombosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.